Ser285
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser285  -  JAM-A (mouse)

Site Information
kVIysQPstRsEGEF   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 467829

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 1 ) , immunoprecipitation ( 11 ) , mass spectrometry ( 3 , 5 , 6 , 7 , 8 , 9 , 10 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 ) , mutation of modification site ( 1 , 11 ) , phospho-antibody ( 1 , 2 , 11 ) , western blotting ( 1 , 2 , 11 )
Disease tissue studied:
anthrax infection ( 14 ) , breast cancer ( 11 ) , melanoma skin cancer ( 20 )
Relevant cell line - cell type - tissue:
'3T3-L1, differentiated' (adipocyte) ( 7 ) , 'epithelial, gallbladder' ( 1 ) , 'fat, brown' ( 15 ) , 293 (epithelial) ( 11 ) , brain ( 15 ) , cholangiocyte-liver ( 1 ) , epididymal ( 2 ) , heart ( 8 , 15 ) , Hepa 1-6 (epithelial) ( 21 ) , hepatocyte-liver ( 1 ) , HL-1 (myocyte) [Akt1 (mouse), knockdown, stable lentiviral expression of Akt1 shRNA] ( 5 ) , HL-1 (myocyte) [Akt2 (mouse), knockdown, stable lentiviral expression of Akt2 shRNA] ( 5 ) , HL-1 (myocyte) ( 5 ) , kidney ( 15 ) , liver ( 3 , 6 , 10 , 15 , 16 , 18 , 19 , 23 ) , liver [Akt2 (mouse), homozygous knockout] ( 22 ) , liver [leptin (mouse), homozygous knockout] ( 10 ) , lung ( 15 ) , MDCKII (epithelial) ( 1 , 11 ) , MEF (fibroblast) [p53 (mouse), homozygous knockout] ( 12 ) , MEF (fibroblast) [Raptor (mouse), knockdown] ( 9 ) , MEF (fibroblast) [RICTOR (mouse), knockdown] ( 9 ) , MEF (fibroblast) [TSC2 (mouse), homozygous knockout] ( 13 ) , MEF (fibroblast) ( 9 ) , mpkCCD (renal) ( 17 ) , MTD-1A (breast cell) ( 11 ) , pancreas ( 15 ) , prostate ( 2 ) , skin [mGluR1 (mouse), transgenic, TG mutant mice] ( 20 ) , spermatozoa ( 2 ) , spleen ( 14 , 15 ) , testis ( 15 )

Upstream Regulation
Regulatory protein:
GPBAR1 (mouse) ( 1 ) , Raptor (mouse) ( 9 ) , RICTOR (mouse) ( 9 ) , TSC2 (mouse) ( 12 )
Putative in vivo kinases:
PKCZ (human) ( 1 , 11 )
Kinases, in vitro:
PKCZ (human) ( 11 )
Putative upstream phosphatases:
PPP2CA (human) ( 11 )
Phosphatases, in vitro:
PPP2CA (human) ( 11 )
Treatments:
DMSO ( 1 ) , insulin ( 7 ) , LY294002 ( 7 ) , RO5527239 ( 1 )

Downstream Regulation
Effects of modification on JAM-A:
activity, induced ( 1 , 2 ) , intracellular localization ( 2 , 11 ) , protein stabilization ( 1 )
Effects of modification on biological processes:
cytoskeletal reorganization ( 11 )

Disease / Diagnostics Relevance
Relevant diseases:
bile-duct cancer ( 1 ) , cholangiocellular carcinoma ( 1 )

References 

1

Merlen G, et al. (2019) TGR5-dependent hepatoprotection through the regulation of biliary epithelium barrier function. Gut
30723104   Curated Info

2

Wu KZ, Li K, Galileo DS, Martin-DeLeon PA (2017) Junctional adhesion molecule A: expression in the murine epididymal tract and accessory organs and acquisition by maturing sperm. Mol Hum Reprod 23, 132-140
28062807   Curated Info

3

Robles MS, Humphrey SJ, Mann M (2017) Phosphorylation Is a Central Mechanism for Circadian Control of Metabolism and Physiology. Cell Metab 25, 118-127
27818261   Curated Info

4

Sacco F, et al. (2016) Glucose-regulated and drug-perturbed phosphoproteome reveals molecular mechanisms controlling insulin secretion. Nat Commun 7, 13250
27841257   Curated Info

5

Reinartz M, Raupach A, Kaisers W, Gödecke A (2014) AKT1 and AKT2 induce distinct phosphorylation patterns in HL-1 cardiac myocytes. J Proteome Res 13, 4232-45
25162660   Curated Info

6

Wilson-Grady JT, Haas W, Gygi SP (2013) Quantitative comparison of the fasted and re-fed mouse liver phosphoproteomes using lower pH reductive dimethylation. Methods 61, 277-86
23567750   Curated Info

7

Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20
23684622   Curated Info

8

Lundby A, et al. (2013) In vivo phosphoproteomics analysis reveals the cardiac targets of β-adrenergic receptor signaling. Sci Signal 6, rs11
23737553   Curated Info

9

Robitaille AM, et al. (2013) Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 339, 1320-3
23429704   Curated Info

10

Grimsrud PA, et al. (2012) A quantitative map of the liver mitochondrial phosphoproteome reveals posttranslational control of ketogenesis. Cell Metab 16, 672-83
23140645   Curated Info

11

Iden S, et al. (2012) aPKC phosphorylates JAM-A at Ser285 to promote cell contact maturation and tight junction formation. J Cell Biol 196, 623-39
22371556   Curated Info

12

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

13

Yu Y, et al. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322-6
21659605   Curated Info

14

Manes NP, et al. (2011) Discovery of mouse spleen signaling responses to anthrax using label-free quantitative phosphoproteomics via mass spectrometry. Mol Cell Proteomics 10, M110.000927
21189417   Curated Info

15

Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89
21183079   Curated Info

16

Possemato A (2010) CST Curation Set: 9735; Year: 2010; Biosample/Treatment: tissue, liver/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

17

Rinschen MM, et al. (2010) Quantitative phosphoproteomic analysis reveals vasopressin V2-receptor-dependent signaling pathways in renal collecting duct cells. Proc Natl Acad Sci U S A 107, 3882-7
20139300   Curated Info

18

Zhou J (2009) CST Curation Set: 7387; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST]
Curated Info

19

Zhou J (2009) CST Curation Set: 7388; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST]
Curated Info

20

Zanivan S, et al. (2008) Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry. J Proteome Res 7, 5314-26
19367708   Curated Info

21

Pan C, Gnad F, Olsen JV, Mann M (2008) Quantitative phosphoproteome analysis of a mouse liver cell line reveals specificity of phosphatase inhibitors. Proteomics 8, 4534-46
18846507   Curated Info

22

Guo A (2007) CST Curation Set: 2989; Year: 2007; Biosample/Treatment: tissue, liver/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

23

Villén J, Beausoleil SA, Gerber SA, Gygi SP (2007) Large-scale phosphorylation analysis of mouse liver. Proc Natl Acad Sci U S A 104, 1488-93
17242355   Curated Info